Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01201577|
Recruitment Status : Completed
First Posted : September 14, 2010
Last Update Posted : June 1, 2011
It has recently been discovered that bacteria are able to communicate using specialised molecules known as Quorum Sensing Signalling Molecules (QSSMs). An accumulation of QSSMs in their surrounding environment allow for the bacteria to quantify the size of colonies. At specific colony sizes the concentration of QSSMs reaches a critical threshold leading to the activation of genes that cause an infection. It is by this mechanism that bacteria within a colony coordinate behaviour to activate infectivity when colony sizes are large enough to withstand defensive measures from the host's immune system. A disruption of quorum sensing may reduce the severity of infection and this has led to the development of inhibitors of quorum sensing as a new strategy in antibacterial therapy.
QSSMs are also thought to facilitate infection by other mechanisms and are able to influence the number and function of a specific type of immune cell known as an 'antigen presenting cell'. These cells are pivotal in allowing the immune system to recognise components of bacteria as foreign and thereby mount the appropriate response. It was found that large numbers of these types of cells underwent programmed cell death (cell suicide) in the presence of QSSMs compared to when QSSMs were absent. This mirrors the situation in blood sampled from patients with severe infections where there is a greater proportion of cell deaths among antigen presenting cells than other types of immune cell.
This study aims to establish in healthy volunteers, the mechanisms by which QSSMs affect immune cells and facilitate the spread of infection. Antibiotic administration in humans can alter the environment of the intestine and can lead to an overgrowth of harmful bacteria to potentially cause an infection. Probiotics supplements can prevent bacterial overgrowth and potentially reduce infective complications. The mechanism, which we aim to clarify, may involve changes in both the production of QSSMs and the function of immune cells.
- Antibiotic use alters gut flora, leading to the appearance in the systemic circulation of bacterial QSSMs and changes in immune function of the host.
- Probiotics and/or prebiotics have beneficial effects by preserving the normal resident gut flora, thereby, modulating bacterial QSSMs and preserving the immune function of the host.
The aims of our study are 2 fold:
- Firstly, to study the effect of orally administered antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
- Secondly, to study the effect of orally administered combinations of prebiotic, probiotic and antibiotic on QSSMs (in faeces and blood) and on innate and adaptive immunity in healthy humans.
|Condition or disease||Intervention/treatment||Phase|
|Quorum Sensing Prebiotics Probiotics Sepsis||Dietary Supplement: Bifidobacterium longum BB536 Dietary Supplement: Active hexose correlated compound (AHCC) Dietary Supplement: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC) Dietary Supplement: Corn starch placebo capsule Drug: Azithromycin||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals|
|Study Start Date :||October 2009|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2011|
|Active Comparator: Placebo/Probiotic||
Dietary Supplement: Bifidobacterium longum BB536
2 capsules odDrug: Azithromycin
|Active Comparator: Placebo/Prebiotic||
Dietary Supplement: Active hexose correlated compound (AHCC)
One capsule tdsDrug: Azithromycin
|Active Comparator: Prebiotic/Probiotic||
Dietary Supplement: Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)
One capsule tds (prebiotic) and two capsules od (probiotic)Drug: Azithromycin
|Placebo Comparator: Placebo/Placebo||
Dietary Supplement: Corn starch placebo capsule
One capsule tds and two capsules odDrug: Azithromycin
- Serum QSSM level [ Time Frame: 14 days ]
- T cell Th1/Th2 ratio [ Time Frame: 14 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01201577
|University of Nottingham|
|Nottingham, Nottinghamshire, United Kingdom, NG7 2UH|
|Principal Investigator:||Abeed Chowdhury, MB ChB BSc MRCS||University of Nottingham|
|Study Director:||Dileep Lobo, MBBS DM FRCS||University of Nottingham|